MedTrace Logo

A Scintigraphic Study to Investigate the Effect of Gelesis100 on Gastric Emptying in Overweight and Obese Subjects

NCT02487602 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2016-08-23

No results posted yet for this study

Summary

The purpose of the study is to evaluate the gastrointestinal behaviour of a novel weight loss device in vivo to further understand the device's mechanism of action in aiding weight loss.

Conditions

Interventions

DEVICE

Gelesis100

Gelesis100 capsules

OTHER

Placebo

Sucrose (sugar) capsules

Sponsors & Collaborators

  • BDD Pharma Ltd

    collaborator INDUSTRY

  • Gelesis, Inc.

    lead INDUSTRY

Principal Investigators

  • Hassan M Heshmati, M.D. · Gelesis, Inc.

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
22 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02487602 on ClinicalTrials.gov